Patents by Inventor Jeannick Cizeau
Jeannick Cizeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9822182Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.Type: GrantFiled: October 2, 2014Date of Patent: November 21, 2017Assignee: VIVENTIA BIO INC.Inventors: Jeannick Cizeau, Arjune Premsukh, Shilpa Chooniedass, Glen MacDonald, Joycelyn Entwistle
-
Publication number: 20160237164Abstract: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab?, F(ab?)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.Type: ApplicationFiled: October 2, 2014Publication date: August 18, 2016Inventors: Jeannick CIZEAU, Arjune PREMSUKH, Shilpa CHOONIEDASS, Glen MACDONALD, Joycelyn ENTWISTLE
-
Publication number: 20150297697Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: ApplicationFiled: December 18, 2014Publication date: October 22, 2015Inventors: Francina C. CHAHAL, Glen MACDONALD, Jeannick CIZEAU
-
Patent number: 9109223Abstract: The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.Type: GrantFiled: December 22, 2006Date of Patent: August 18, 2015Assignee: Viventia Bio, Inc.Inventors: Adrian Schwartz Mittelman, Jeannick Cizeau, Nicholas Ronald Glover, Glen Christopher MacDonald
-
Publication number: 20150197575Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: January 23, 2015Publication date: July 16, 2015Inventors: Nicholas Ronald GLOVER, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Patent number: 8999334Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: GrantFiled: March 26, 2013Date of Patent: April 7, 2015Assignee: Viventia Bio Inc.Inventors: Francina C. Chahal, Jeannick Cizeau
-
Patent number: 8969540Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: January 17, 2013Date of Patent: March 3, 2015Assignee: Viventia Bio Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina C. Chahal
-
Patent number: 8946390Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: GrantFiled: January 25, 2013Date of Patent: February 3, 2015Assignee: Viventia Bio Inc.Inventors: Francina C. Chahal, Glen MacDonald, Jeannick Cizeau
-
Publication number: 20150018526Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: ApplicationFiled: April 1, 2014Publication date: January 15, 2015Applicant: Merck Patent GmbHInventors: Matthew BAKER, Francis J. CARR, Koen HELLENDOORN, Jeannick CIZEAU, Glen C. MACDONALD, Joycelyn ENTWISTLE, Denis G. BOSC, Nicholas R. GLOVER
-
Patent number: 8716234Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.Type: GrantFiled: May 21, 2010Date of Patent: May 6, 2014Assignee: Merck Patent GmbHInventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
-
Patent number: 8697075Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.Type: GrantFiled: November 16, 2011Date of Patent: April 15, 2014Assignee: Viventia Bio Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Francina C. Chahal
-
Publication number: 20130344076Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: ApplicationFiled: March 26, 2013Publication date: December 26, 2013Applicant: Viventia Bio Inc.Inventors: Francina C. CHAHAL, Jeannick CIZEAU
-
Publication number: 20130243799Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: ApplicationFiled: January 25, 2013Publication date: September 19, 2013Applicant: VIVENTIA BIOTECHNOLOGIES INC.Inventors: Francina C. CHAHAL, Glen MACDONALD, Jeannick CIZEAU
-
Publication number: 20130217865Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: ApplicationFiled: January 17, 2013Publication date: August 22, 2013Applicant: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, Francina C. Chahal
-
Patent number: 8426561Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Nuclear Factor Kappa-B inhibitor beta (NFKBIB). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or a label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies herein. Further, the application provides novel cancer-associated epitopes and antigens of variant NFKBIB, and uses thereof.Type: GrantFiled: November 27, 2008Date of Patent: April 23, 2013Inventors: Francina C. Chahal, Jeannick Cizeau
-
Patent number: 8389286Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.Type: GrantFiled: April 26, 2011Date of Patent: March 5, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Francina C. Chahal, Glen MacDonald, Jeannick Cizeau
-
Patent number: 8383117Abstract: The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.Type: GrantFiled: June 10, 2005Date of Patent: February 26, 2013Assignee: Viventia Biotechnologies Inc.Inventors: Nicholas Ronald Glover, Glen Christopher MacDonald, Joycelyn Entwistle, Jeannick Cizeau, Denis Georges Bosc, Francina C. Chahal
-
Publication number: 20130039931Abstract: The present application provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens, and uses thereof.Type: ApplicationFiled: August 22, 2012Publication date: February 14, 2013Inventors: Jeannick Cizeau, Francina C. Chahal
-
Patent number: 8318472Abstract: An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the VH region, VL region, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in an Escherichia coli expression system.Type: GrantFiled: September 26, 2008Date of Patent: November 27, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Glen MacDonald, Arjune Premsukh
-
Patent number: 8273550Abstract: The present application provides the amino acid and nucleic acid sequences of heavy and light chain complementarity determining regions of a cancer specific antibody directed to an epitope of variant Heterogeneous Ribonucleoprotein G (HnRNPG). In addition, the application provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods of uses thereof. The application also relates to diagnostic methods and kits using the cancer specific antibodies disclosed herein. Further, the application provides novel cancer-associated epitopes and antigens of variant HnRNPG, and uses thereof.Type: GrantFiled: October 23, 2008Date of Patent: September 25, 2012Assignee: Viventia Biotechnologies Inc.Inventors: Jeannick Cizeau, Francina C. Chahal